A perspective on multi-target drugs for Alzheimer's disease
O Benek, J Korabecny, O Soukup - Trends in pharmacological sciences, 2020 - cell.com
Alzheimer's disease (AD) has a complex pathophysiology that includes aggregation of
pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia …
pathological proteins, impaired neurotransmission, increased oxidative stress, or microglia …
Management of mild cognitive impairment (MCI): the need for national and international guidelines
Objectives: To review available evidence of pharmacological and non-pharmacological
treatment for MCI and analyse information and limitations in national and international …
treatment for MCI and analyse information and limitations in national and international …
Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial
Context Many observational studies have shown that physical activity reduces the risk of
cognitive decline; however, evidence from randomized trials is lacking. Objective To …
cognitive decline; however, evidence from randomized trials is lacking. Objective To …
Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review
J Rodakowski, E Saghafi, MA Butters… - Molecular aspects of …, 2015 - Elsevier
The purpose of this scoping review was to examine the science related to non-
pharmacological interventions designed to slow decline for older adults with Mild Cognitive …
pharmacological interventions designed to slow decline for older adults with Mild Cognitive …
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes
an overwhelming health, social, economic, and political problem to nations. Unless a new …
an overwhelming health, social, economic, and political problem to nations. Unless a new …
Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology
The British Association for Psychopharmacology coordinated a meeting of experts to review
and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As …
and revise its previous 2011 guidelines for clinical practice with anti-dementia drugs. As …
Treatment for mild cognitive impairment: systematic review
Background More people are presenting with mild cognitive impairment (MCI), frequently a
precursor to dementia, but we do not know how to reduce deterioration. Aims To …
precursor to dementia, but we do not know how to reduce deterioration. Aims To …
[HTML][HTML] Acetylcholine bidirectionally regulates learning and memory
Q Huang, C Liao, F Ge, J Ao, T Liu - Journal of Neurorestoratology, 2022 - Elsevier
Acetylcholine (ACh) is one of the most important neurotransmitters in the central cholinergic
system; it specifically binds to muscarinic and nicotinic receptors and is degraded by …
system; it specifically binds to muscarinic and nicotinic receptors and is degraded by …
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials
R Raschetti, E Albanese, N Vanacore… - PLoS medicine, 2007 - journals.plos.org
Background Mild cognitive impairment (MCI) refers to a transitional zone between normal
ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical …
ageing and dementia. Despite the uncertainty regarding the definition of MCI as a clinical …
Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis
AC Tricco, C Soobiah, S Berliner, JM Ho, CH Ng… - Cmaj, 2013 - Can Med Assoc
Background: Cognitive enhancers, including cholinesterase inhibitors and memantine, are
used to treat dementia, but their effectiveness for mild cognitive impairment is unclear. We …
used to treat dementia, but their effectiveness for mild cognitive impairment is unclear. We …